## Abstract The paraneoplastic syndrome of cachexia is considered a degenerative chronic inflammatory disease, being deeply related to the increase of pro‐inflammatory factors, especially tumour necrosis factor alpha (TNF‐__α__). It is known that the adipose tissue is affected by cachexia and contr
Diminished visceral adipose tissue in cancer cachexia
✍ Scribed by Hiroyuki Ogiwara; Seiichi Takahashi; Yutaro Kato; Ichiro Uyama; Tetsuya Takahara; Kaichiro Kikuchi; Shuhei Iida
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 462 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
To estimate the relationship between the visceral adipose tissue (AT) area and cancer cachexia, 13 cachectic patients (7 males, 6 females; age 65.2 ± 11.0 years; body mass index 20.8 ± 4.1 kg/m^2^) were examined by computed tomography (CT) scanning. Cachectic cancer patients who had a 10% decrease of body weight and died within 6 months because of gastrointestinal carcinoma had a significantly smaller visceral AT area than control subjects (mean ± sd: 43.9 ± 42.2 cm^2^ vs. 93.4 ± 56.0 cm^2^, P < 0.05, P=0.014). Otherwise, there were no significant differences between the visceral AT areas of cachectic cancer patients and those of cancer patients with resectable tumors treated by curative operation (mean ± sd: 68.8 ± 57.7 cm^2^) (NS, P=0.206). There was, however, a tendency for cachectic cancer patients to have a smaller visceral AT area than those with resectable tumors. This result suggests that the visceral AT area is not preserved in the cachectic state associated with cancer. © 1994 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Adipocytes from post‐menopausal females have higher basal lipolytic rates than pre‐menopausal females, which contributes to increased risk of developing dyslipidemia following menopause. The purpose of this study was to delineate cellular mechanisms affecting adipose tissue function in
## Abstract This study investigated the anti‐obesity effects of fucoxanthin in diet‐induced obesity mice fed a high‐fat diet (20% fat, wt/wt). The mice were supplemented with two doses of fucoxanthin (0.05 and 0.2%, wt/wt) for 6 wk. Fucoxanthin significantly lowered body weight and visceral fat‐pad